Prostate-specific antigen velocity calculated with three measurements as previously described 10 is contestable, as it is an average of two or more mean velocities. In 13 cases, PSA velocity could ...
Authors Stacy Loeb, E. Jeffrey Metter et al published a way to assess cancer risk by assigning “risk values” to PSA progression. They developed a simple formula for calculating prostate cancer risk based on PSA velocity using a threshold of <0.4 ng/mL rise per year as being zero risk. (This threshold was based on previous studies done by ...
several studies indicate that when psa levels increase sharply in the months before surgery, the cancer is likely to be aggressive. a significant rise is 50% within 6 months.
PSA density was calculated as total PSA (ng/ml) divided by prostate volume (ml). Main endpoint was clinically significant cancer (csPCa) defined as Gleason Score ≥ 7. Results: The median PSA-density was 0.10 ng/ml 2 (IQR 0.075-0.14). PSA-density was associated with the risk of finding csPCa both with and without adjusting for the additional ...
The prostate-specific antigen (PSA) test is a screening test for prostate cancer, as well as a method for monitoring the treatment of the disease and testing for recurrence.Like other early detection cancer screening tests, it is designed to alert a person to the presence of disease before any symptoms occur. At the current time, most prostate cancers are detected in this way, via this blood ...
Physicians fine-tune PSA velocity measurements to improve cancer detection Factors like age, PSA history and the presence of prostatitis are adding more relevance to PSA velocity measurements.
PSA velocity after surgery. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy. New England Journal of Medicine 2004;351:125–35. PMID: 15247353.
The calculator takes into account prostate-specific antigen (PSA) testing, family history, rectal examinations, and history of a prior negative prostate biopsy. Though PSA testing is widely used to assess prostate cancer risk, it does have limitations.
Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103:462. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.